Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

NCT ID: NCT04322734

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-13

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate.

This study is currently recruiting.

There is no cost for visits or study-related exams.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mitochondria are essential for a wide range of functions in almost every cell in our body. Best known for their role in adenosine triphosphate (ATP) production, mitochondria are also closely involved in a wide variety of cell functions such as calcium buffering, redox regulation, apoptosis and inflammation, and regulate metabolism through several mechanisms, including epigenetic changes. ATP produced is essential for many cellular systems. Thus, abnormal mitochondrial function can adversely affect cellular systems by several mechanisms.

Given the important role of the mitochondria in cellular function, individuals with classic mitochondrial disease demonstrate devastating symptoms, particularly in tissues that have high-energy demands such as the brain, muscles, gastrointestinal (GI) tract and immune system. Mitochondrial dysfunction contributes to the pathophysiology of more common diseases, including psychiatric diseases, neurodegenerative disorders, neurological disorders including migraine and seizures, persistent systemic inflammation, cardiac disease, cancer and diabetes. Mitochondrial dysfunction also effects a significant portion of individuals with autism spectrum disorder (ASD) as well as genetic syndromes associated with ASD.

One of our goals is to develop a method using the Seahorse Analyzer to measure individual variations in mitochondrial function which can identify children with medical disorders and mitochondrial dysfunction without an invasive muscle biopsy. In order to establish comprehensive profiles of mitochondrial function for individuals with known neurological and neurodevelopmental disorders, we will compare blood, urine, and stool from these individuals to those of healthy, typically developing (TD) children. The relationship between mitochondrial function, development, and behavior will be assessed by performing standard developmental testing. In addition, in patients who have a procedure that produces leftover tissue, we will examine the mitochondrial function in that tissue and correlate it with findings from blood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder Mitochondrial Pathology Epilepsy Brain Tumor Psychiatric Disorder Mitochondrial Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASD (General)

150 children with ASD and unknown MD status

No interventions assigned to this group

ASD (With MD)

50 children with ASD and confirmed MD

No interventions assigned to this group

ASD (No MD)

50 children with ASD and ruled out MD

No interventions assigned to this group

Epilepsy

50 children with epilepsy (primary) and no ASD

No interventions assigned to this group

Brain Tumor

50 children with brain tumor (primary) and no ASD

No interventions assigned to this group

Psychiatric Disorder

50 children with psychiatric disorder (primary) and no ASD, using lithium treatments

No interventions assigned to this group

MD (No ASD)

50 children with MD (primary) and no ASD

No interventions assigned to this group

TD (With ASD Sibling)

50 TD children with a sibling with ASD/neurodevelopmental delay

No interventions assigned to this group

TD (No ASD Sibling)

50 TD children with no siblings with ASD/neurodevelopmental delay

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASD, as defined by either a gold standard measure for ASD diagnosis, the Autism Diagnostic Observation Schedule (ADOS); the Autism Diagnostic Interview-Revised (ADI-R); and/or a comprehensive assessment that is consistent with ASD, in the opinion of the principal investigator. For those the PI believes a prospective diagnosis of ASD is warranted, a formal diagnostic assessment will be scheduled at screening.
2. 0 years through 17 years 11 months of age


1\. 0 years to 17 years 11 months of age

Exclusion Criteria

1. History of a significant adverse reaction to a prior blood draw
2. In females of reproductive age, pregnancy or plans to become pregnant
3. Any other historical event/information that may, in the opinion of the PI, be a reason to exclude the child from participation.
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

State University of New York - Downstate Medical Center

OTHER

Sponsor Role collaborator

Southwest Autism Research & Resource Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard Frye

Principal Investigator and Sponsor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard E Frye, MD, PhD

Role: STUDY_DIRECTOR

Autism Discovery & Treatment Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwestern Research and Resource Center

Phoenix, Arizona, United States

Site Status RECRUITING

State University of New York, Downstate

Brooklyn, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Richard E Frye, MD, PhD

Role: CONTACT

Phone: 844-ADTFRes

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christopher J Smith, PhD

Role: primary

Sophia Crisler

Role: backup

Harris Huberman, MD

Role: primary

Daniel Mishan

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Mito Tissue

Identifier Type: -

Identifier Source: org_study_id